Heron Therapeutics CFO Ira Duarte Buys Shares

Ira Duarte, the Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. (NasdaqCM: HRTX), recently bought 12,500 shares of the company on June 16, 2026. The transaction did not occur under a pre-planned trading program. At the time of the purchase, Heron Therapeutics' stock was trading at $0.38 per share.

Insider Buying and Selling at Heron Therapeutics, Inc.

On June 16, 2026, Ira Duarte, EVP and CFO of Heron Therapeutics, bought 12,500 shares. Additionally, Duarte sold 3,555 shares on the same day. The transactions were not part of a pre-arranged trading plan. Another executive, William Forbes, EVP and Chief Development Officer, also bought 12,500 shares on June 6, 2026.

Other Institutional Activity in Heron Therapeutics

Several institutional investors have made moves in Heron Therapeutics. Rubric Capital Management LP holds 30,046,828 shares valued at approximately $24 million, showing no change in their position. Clearline Capital LP also maintained its holdings with 12,235,239 shares worth about $9.8 million. BlackRock, Inc. reduced its stake by 111,814 shares, bringing its total to 10,106,422 shares valued at $8 million. In contrast, OrbiMed Advisors LLC and Vanguard Capital Management LLC significantly increased their positions, each adding millions of shares.

Heron Therapeutics Stock Snapshot

Heron Therapeutics, trading on the NasdaqCM under the ticker HRTX, recently saw its shares priced at $0.38. The company has a market capitalization of approximately $71.9 million and a beta of 1.572, indicating higher volatility compared to the market. The stock's 52-week range spans from $0.38 to $2.30. Its 50-day moving average is $0.8702, and the 200-day moving average is $1.11825. The company faces a high debt-to-equity ratio of 1550.115, but maintains a current ratio of 2.53 and a quick ratio of 1.419.

Recent Earnings

Heron Therapeutics reported revenue of $150.7 million, although the company experienced a revenue decline of 10.8%. The net margin stands at -20.53%, reflecting ongoing challenges in profitability. The company reported an EPS of -$0.18. Investors are looking forward to the next earnings release on August 7, 2026.

Analysts Set New Price Targets

Analysts have shown optimism about Heron Therapeutics' prospects. On June 3, 2026, HC Wainwright & Co. maintained a 'buy' rating with a price target of $2.00. The consensus among analysts is a 'buy' recommendation, with a mean price target of $3.00, based on two analyst opinions.

About Heron Therapeutics

Heron Therapeutics, Inc. is a biotechnology company based in Cary, North Carolina. It focuses on developing and commercializing therapies that improve medical care, using its proprietary Biochronomer technology. This technology allows for the extended release of drugs over days to weeks with a single administration. The company's products include SUSTOL for chemotherapy-induced nausea and vomiting, and CINVANTI for similar uses. Heron is also developing ZYNRELEF, a local anesthetic, and APONVIE, for postoperative nausea.

Bottom Line

Ira Duarte's recent purchase of Heron Therapeutics shares highlights insider confidence in the company. While the stock has seen volatility, analysts maintain a positive outlook with a 'buy' recommendation. Investors will be watching the next earnings report closely for signs of progress in their financial performance.